
Komal Jhaveri: OS Benefit with Adjuvant Abemaciclib in High-Risk Breast Cancer
Komal Jhaveri, Medical Oncologist and Clinical Researcher of Breast Medicine and Early Drug Development S, Section Head of Endocrine Therapy, Breast Medicine Service, and Clinical Director of Early Drug Development Service at Memorial Sloan Kettering Cancer Center, shared a post on X:
“Fantastic news for patients! OS benefit with adjuvant abemaciclib for 2 years for high-risk node-positive patients. Congratulations to everyone involved with the monarchE trial. Awaiting details at an upcoming meeting.”
Naoto T Ueno, Director of the University of Hawai’i Cancer Center, shared this post, adding:
“A significant milestone to show the OS improvement. The next step is to review the magnitude, toxicity, and cost to define the impact on long-term care. It is still 300K per treatment, and many people drop out.”
More posts featuring Komal Jhaveri and Naoto T Ueno.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023